Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 07, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
On March 06, 2007, the GlaxoSmithKline Employee Trust ("the GSK Trust") executed the following transactions:
- Transferred 2,731 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Sold 11,887 Ordinary Shares at a price of GBP 14.10 on behalf of participants in the GlaxoSmithKline Share Value Plan.
- Transferred 47,122 Ordinary Shares to participants in the GlaxoSmithKline Share Value Plan.
These transactions were advised to the Company on March 07, 2007.
Management Commentary and Risks
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop—are noted as having an interest in the shares held within the GSK Trust in the same capacity as other employees. The filing contains no specific guidance, outlook, or discussion of unusual items beyond these routine trust activities.
Investor Verification Points
- Verify the total number of shares transferred and sold by the GSK Trust on March 06, 2007.
- Confirm the transaction price of GBP 14.10 per share for the sold portion.
- Review the specific plans (SmithKline Beecham Employee Share Option Plan 1991 and GlaxoSmithKline Share Value Plan) involved in the share transfers.
- Note that this filing does not contain financial performance data for the period.